Sequence: Ac-rrrrrrrrr-NH2
antisense oligonucleotide (AON)
| Experiment Id | EXP000665 |
|---|---|
| Paper | Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castra |
| Peptide | D-r9 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | varied (N/P ratios 1–5) |
| Rna Concentration | 0.2–0.5 µM (0.35 µM optimal) |
| Mixing Ratio | N/P ratio 1–5 (optimal = 3) |
| Formulation Format | CPP/AON polyplex |
| Formulation Components | CPP + antisense oligonucleotide (noncovalent complex) |
| Size Nm | 80.00 |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | 22Rv1; DuCaP; VCaP; HeLa; MIA PaCa-2 |
| Animal Model | |
| Administration Route | |
| Output Type | splice correction / mRNA knockdown |
| Output Value | PF14 achieved ~37–59% AR-V7 mRNA reduction; others minimal |
| Output Units | |
| Output Notes | PF14 showed highest uptake, partial nuclear localization, and significant AR-V7 knockdown with reduced androgen-independent proliferation; hLF, L-R9, D-r9 showed uptake but no functional splice correction. |
| Toxicity Notes | PF14 showed moderate carrier-associated toxicity at longer incubation; others minimal |
| Curation Notes |